Vozmozhnosti primeneniya beta-adrenoblokatorov v lechenii serdechnososudistykh zabolevaniy u bol'nykh khronicheskoy obstruktivnoy bolezn'yu legkikh


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the evaluation of potentials for the use of ß-adrenoblockers (BAB) in the treatment of cardiovascular diseases (CVD) in patients with chronic obstructive pulmonary disease (COPD), including coronary heart disease, hypertension, inherited connective-tissue diseases, etc. Currently, the use of cardioselective beta blockers: bisoprolol, metoprolol succinate, nebivolol, as well as α 1-and β-blocker carvedilol is recommended for the treatment of patients with CVD and COPD. The control of respiratory function (RF) is necessary against the background of use of these BAB. In the case of worsening bronchial obstruction and adverse influence on respiratory function parameters, the dosage of beta blockers should be reduced, and in the case of depression of respiratory function, the use of these drugs should be discontinued. In general, the use of cardioselective beta blockers and carvedilol in patients with CVD and COPD is safe, and benefits of this group of drugs overweigh the risks of exacerbation of COPD.

Full Text

Restricted Access

References

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd. org/uploads/ users/ files/GOLD_ Report_ 2013_ Feb20.pdf.
  2. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-32.
  3. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-43.
  4. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875-81.
  5. Schirnhofer L, Lamprecht B, Vollmer WM, et al. Results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 2007;131:29-36.
  6. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370;741-50.
  7. Хроническая обструктивная болезнь легких. Федеральная программа / Под редакцией А.Г. Чучалина. 2-е издание, переработанное и дополненное. М., 2004. 61 с.
  8. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006;3:e442.
  9. Стаценко М.Е., Деревянченко М.В. Место -адреноблокаторов в лечении сердечнососудистых заболеваний у больных хронической обструктивной болезнью легких // Кардиология. 2012. № 12. С. 107-13.
  10. Barnes PJ, Celli BP. Systemic manifestations and comorbidities of CORD. Eur Respir J 2009;33:1165-85.
  11. Стаценко М.Е. Особенности лечения артериальной гипертензии у больных хронической обструктивной болезнью легких / Труды XV Российского национального Конгресса "Человек и лекарство". М., 2009. Т. 1. С. 418-31.
  12. Дворецкий Л.И. Артериальная гипертония у больных ХОБЛ// РМЖ. 2003. №11. С. 21-8.
  13. Адашева Т.В., Задионченко В.С., Мациевич М.В. и др. Артериальная гипертония и хроническая обструктивная болезнь легких -рациональный выбор терапии // РМЖ 2006. № 10. С. 795-800.
  14. Гурова А.Ю., Чаплыгин А.В., Свет Т.Е. и др. Особенности рациональной фармакотерапии бета-адреноблокаторами при сочетании ишемической болезни сердца и хронической обструктивной болезни легких // Лечащий врач 2012. № 2: www.lvrach.ru/2012/02
  15. Шепеленко А.Ф., Миронов М.Б., Сидоров Ю.О. Комплексное лечение обострений хронической обструктивной болезни легких //Лечащий врач 2006. № 8. С. 14-6.
  16. Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med 2002;28:1701-707.
  17. Wellstein A, Palm D, Belz GG, et al. Concentration kinetics of propranolol, bisoprolol and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. J Cardiovasc Pharmacol 1986;8(Suppl.11):41-5.
  18. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 2-е издание, перераб. и доп. М., СПб., 2002. 926 с.
  19. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. JACC 2004;44(3):497-502.
  20. Чазова И.Е. Артериальная гипертония и хроническая обструктивная болезнь легких // Consilium-Medicum. 2006. № 5: http://www. consilium-medicum.com
  21. Thompson WH, Nielsen CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
  22. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25:1341-62.
  23. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. JACC 2001;37:1950-56.
  24. Dranseld MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-05.
  25. Толпыгина С.Н., Марцевич С.Ю. Бисопролол в лечении артериальной гипертензии // Фарматека 2008. № 20. С. 114-21.
  26. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. JACC 2010;55(17):1780-87.
  27. Стаценко М.Е., Иванова Д.А., Спорова О.Е. и др. Применение в-адреноблокаторов у больных с хронической сердечной недостаточностью и сопутствующей хронической обструктивной болезнью легких // Кардиоваскулярная терапия и профилактика 2008. № 8. С. 58-63.
  28. Michele TM, Pinheiro S, Lyasu S. The safety of tiotropium - the FDA conclusions. N Engl J Med 2010;363:1097-99.
  29. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11:292-98.
  30. Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010;12:685-91.
  31. Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (третий пересмотр) // Сердечная недостаточность 2010. Т. 11. № 1.
  32. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. Eur J Heart Fail 2012;14:803-69.
  33. Hawkins NM, Jhund PS, Simpson CR, et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010;12:17-24.
  34. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane database of systematic reviews 2005;CD003566.
  35. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009;11:684-90.
  36. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. JACC 2010;55:1780-87.
  37. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
  38. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719-25.
  39. Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964-69.
  40. Stallberg B, Selroos O, Vogelmeier C, et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res 2009;10:11.
  41. Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012). http://www.scardio.ru/content/Guidelines/ Rekomendations_fibrillyacia_predserdii_ 2012.pdf
  42. The 2012 focused update of the ESC Guidelines for the Management of patients with Atrial Fibrillation. doi: 10.1093/eurheartj/ehs253.
  43. Ram FS. Use of theophylline in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2006;12:132-39.
  44. Национальные рекомендации по определению риска и профилактике внезапной сердечной смерти (2012 г.) http:// www. scardio. ru/rekomendacii/rekomenda cii_ rko/nacionalnye_rekomendacii_po_opredele-niyu_riska_i_profilaktike_vnezapnoy_serdech-noy_smerti/
  45. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/ AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). JАCC 2006;48:1064-108.
  46. Бокерия Л.А., Ревишвили А.Ш., Неминущий Н.М. Внезапная сердечная смерть. М., 2011. 272 с.
  47. Dargie H.J. Effect CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001;357:1385-90.
  48. Goldstein S, Fagerberg B, Hjalmarson A, et al. For the MERIT-HF Study Group. Metoprololcontrolled release/extended release in patient with severe heart failure. JАСС 2001;38:932-38.
  49. Lechat Ph. The cardiac Insufficiency Bisoprolol Study - II (CIBIS - II): a randomised trial. Lancet 1999;353:9-13.
  50. Национальные рекомендации по диагностике и лечению артериальной гипертензии // Кардиоваскулярная терапия и профилактика 2008. № 7. Прил. 2.
  51. Обновление Европейских рекомендаций по лечению артериальной гипертензии: анализ Европейского общества гипертензии // Артериальная гипертензия 2010. № 1. С. 4-42.
  52. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58.
  53. Российские рекомендации по наследственным нарушениям соединительной ткани (I пересмотр) // Российский кардиологический журнал 2013. № 1. Прил. 1.
  54. Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. Am J Med Genet 1998;77(1):31-7.
  55. Gazit Y, Nahir M, Grahame R, et al. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003;15:33-40.
  56. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/ STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JАСС 2010;55 (14): e27-129.
  57. Schaal SF. Ventricular arrhythmias in patients with mitral valve prolapse. Cardiovasc Clin 1992;22:307-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies